中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
5期
31-33
,共3页
阎振武%李淑花%陈建红%高凤至%王万朋
閻振武%李淑花%陳建紅%高鳳至%王萬朋
염진무%리숙화%진건홍%고봉지%왕만붕
阿德福韦酯%苦参素%乙型肝炎%慢性%药物疗法,联合
阿德福韋酯%苦參素%乙型肝炎%慢性%藥物療法,聯閤
아덕복위지%고삼소%을형간염%만성%약물요법,연합
Adefovir dipivoxil%Oxymatrine%Hepatits B,chronic%Drug therapy%Combination
目的 观察阿德福韦酯和苦参素联合治疗HBeAg阳性慢性乙型肝炎患者的疗效.方法 将132例HBeAg阳性的慢性乙型肝炎患者随机分为联合治疗组70例,给予阿德福韦酯10 mg/d,苦参素胶囊450 mg/d;单用组62例,仅给予阿德福韦酯治疗.观察治疗12周、24周、52周时应答反应情况.结果 肝功能复常率在12周时联合组优于单用组(P<0.05),在24周、52周时差异无统计学意义(P>0.05).联合组和单用组HBVDNA阴转率12周时分别为22.2%和20.0%,24周时分别为36.1%和31.6%,两组比较差异无统计学意义(P>0.05),但52周时别为61.1%和46.7%,两组比较差异有统计学意义(P<0.05);联合组和单用组HBeAg/HBeAb血清转换率在12周时分别为6.9%和5.0%,两组比较差异无统计学意义(P>0.05),但在第24周(分别为22.2%、11.7%)、第52周(分别为40.2%、20%)时,两组比较差异有统计学意义(P<0.05,P<0.01).两组患者在治疗过程中,均未发现明显不良反应.结论 阿德福韦酯和苦参素联合应用能显著提高对HBeAg阳性慢性乙型肝炎患者的抗病毒疗效.
目的 觀察阿德福韋酯和苦參素聯閤治療HBeAg暘性慢性乙型肝炎患者的療效.方法 將132例HBeAg暘性的慢性乙型肝炎患者隨機分為聯閤治療組70例,給予阿德福韋酯10 mg/d,苦參素膠囊450 mg/d;單用組62例,僅給予阿德福韋酯治療.觀察治療12週、24週、52週時應答反應情況.結果 肝功能複常率在12週時聯閤組優于單用組(P<0.05),在24週、52週時差異無統計學意義(P>0.05).聯閤組和單用組HBVDNA陰轉率12週時分彆為22.2%和20.0%,24週時分彆為36.1%和31.6%,兩組比較差異無統計學意義(P>0.05),但52週時彆為61.1%和46.7%,兩組比較差異有統計學意義(P<0.05);聯閤組和單用組HBeAg/HBeAb血清轉換率在12週時分彆為6.9%和5.0%,兩組比較差異無統計學意義(P>0.05),但在第24週(分彆為22.2%、11.7%)、第52週(分彆為40.2%、20%)時,兩組比較差異有統計學意義(P<0.05,P<0.01).兩組患者在治療過程中,均未髮現明顯不良反應.結論 阿德福韋酯和苦參素聯閤應用能顯著提高對HBeAg暘性慢性乙型肝炎患者的抗病毒療效.
목적 관찰아덕복위지화고삼소연합치료HBeAg양성만성을형간염환자적료효.방법 장132례HBeAg양성적만성을형간염환자수궤분위연합치료조70례,급여아덕복위지10 mg/d,고삼소효낭450 mg/d;단용조62례,부급여아덕복위지치료.관찰치료12주、24주、52주시응답반응정황.결과 간공능복상솔재12주시연합조우우단용조(P<0.05),재24주、52주시차이무통계학의의(P>0.05).연합조화단용조HBVDNA음전솔12주시분별위22.2%화20.0%,24주시분별위36.1%화31.6%,량조비교차이무통계학의의(P>0.05),단52주시별위61.1%화46.7%,량조비교차이유통계학의의(P<0.05);연합조화단용조HBeAg/HBeAb혈청전환솔재12주시분별위6.9%화5.0%,량조비교차이무통계학의의(P>0.05),단재제24주(분별위22.2%、11.7%)、제52주(분별위40.2%、20%)시,량조비교차이유통계학의의(P<0.05,P<0.01).량조환자재치료과정중,균미발현명현불량반응.결론 아덕복위지화고삼소연합응용능현저제고대HBeAg양성만성을형간염환자적항병독료효.
Objective To evaluate the efficacy of adefovir dipivoxil and oxymatrine combination therapy in treatment of patients with HBeAg-positive chronic hepatitis B(CHB). Methods One hundred and thirty-two patients with HBeAg-positive CHB were randomly divided into two groups:70 patients in combination therapy group were given adefovir dipivoxil 10 mg/d and oxymatrine 450 mg/d,62 patients in adefovir dipivoxil monotherapy. Evaluation were performed at week 12,24 and 52,respectively. Results At week 12,the normalization rate of aminotransferase in combination group was higher than it in monotherapy group(P<0.05),but there was no difference between the two groups at week 24(P>0.05)and 52(P>0.05).The HBV DNA undetectable rate in combination group and monotherapy group was 22.2% and 20.0% at week 12(P<0.05),36.1% and 31.6% at week 24(P<0.05),61.1% and 46.7% at week 52(P>0.05). The seroconversion rate of HBeAg/HBeAb in combination group and monotherapy group were 6.9% and 5.0% at week 12 (P>0.05),but it differed between the two groups at week 24(22.2% VS 11.7%,P<0.05)and at week 52(40.2% VS 20%,P<0.05).No severe adverse reaction was found in both groups. Conclusions Adefovir dipivoxil and oxymatrine combination therapy could enhance the antiviral effects in patients with HBeAg-positive CHB.
